BACKGROUND: Major goals of concurrent radiation and chemotherapy in the treatment of esophageal cancer are the early restoration and long-term maintenance of swallowing function. The purpose of this study was to determine the impact of concurrent radiation and chemotherapy on swallowing function. METHODS: Between September 1980 and September 1990, 120 patients with esophageal cancer were treated at the Fox Chase Cancer Center on the basis of one of three prospective nonrandomized protocols using concurrent chemotherapy and radiation. Swallowing function was retrospectively assessed in these patients by use of a swallowing-function scoring system. In addition, patients who had long-term control of their esophageal cancer underwent a more detailed analysis of swallowing function. RESULTS: Initial improvement in dysphagia occurred in 88% of the 102 assessable patients, with a median time to improvement of 2 weeks. There was no difference in overall percentage of initial improvement for patients with adenocarcinoma versus squamous cell carcinoma. Patients with distal tumors, however, showed both earlier and higher frequency of initial improvement than did patients with tumors in the upper two-thirds of the thoracic esophagus (95% versus 79%). Local relapse-free survival of definitively treated patients at 3 years was 60% and was significantly better for patients with Stage I (76%) versus Stage II cancers (55%) (P < 0.05). All 25 patients treated with curative intent who survived for more than 1 year without evidence of disease were able to eat soft or solid foods and had a benign stricture rate of only 12%. Even in patients with advanced disease who were treated with palliative intent, 91% had an initial improvement in swallowing function and 67% had improvement in swallowing function that lasted until death. CONCLUSIONS: High-dose concurrent radiation and chemotherapy provides rapid improvement in dysphagia, and this improvement results in normal or near-normal swallowing function of long duration.
BACKGROUND: Major goals of concurrent radiation and chemotherapy in the treatment of esophageal cancer are the early restoration and long-term maintenance of swallowing function. The purpose of this study was to determine the impact of concurrent radiation and chemotherapy on swallowing function. METHODS: Between September 1980 and September 1990, 120 patients with esophageal cancer were treated at the Fox Chase Cancer Center on the basis of one of three prospective nonrandomized protocols using concurrent chemotherapy and radiation. Swallowing function was retrospectively assessed in these patients by use of a swallowing-function scoring system. In addition, patients who had long-term control of their esophageal cancer underwent a more detailed analysis of swallowing function. RESULTS: Initial improvement in dysphagia occurred in 88% of the 102 assessable patients, with a median time to improvement of 2 weeks. There was no difference in overall percentage of initial improvement for patients with adenocarcinoma versus squamous cell carcinoma. Patients with distal tumors, however, showed both earlier and higher frequency of initial improvement than did patients with tumors in the upper two-thirds of the thoracic esophagus (95% versus 79%). Local relapse-free survival of definitively treated patients at 3 years was 60% and was significantly better for patients with Stage I (76%) versus Stage II cancers (55%) (P < 0.05). All 25 patients treated with curative intent who survived for more than 1 year without evidence of disease were able to eat soft or solid foods and had a benign stricture rate of only 12%. Even in patients with advanced disease who were treated with palliative intent, 91% had an initial improvement in swallowing function and 67% had improvement in swallowing function that lasted until death. CONCLUSIONS: High-dose concurrent radiation and chemotherapy provides rapid improvement in dysphagia, and this improvement results in normal or near-normal swallowing function of long duration.
Authors: B S Anand; Z A Saeed; P A Michaletz; C B Winchester; M A Doherty; J H Liem; D Y Graham Journal: Dig Dis Sci Date: 1998-10 Impact factor: 3.199
Authors: Sun Hyun Bae; Won Park; Doo Ho Choi; Heerim Nam; Won Ki Kang; Young Suk Park; Joon Oh Park; Ho Kyung Chun; Woo Yong Lee; Seong Hyeon Yun; Hee Cheol Kim Journal: Radiat Oncol Date: 2011-05-21 Impact factor: 3.481
Authors: Sujai Jalaj; Sang Yeob Lee; Camille McGaw; Bijo K John; Zuofeng Li; Ziad T Awad; James S Scolapio; Juan C Munoz Journal: Endosc Int Open Date: 2014-10-24
Authors: Mohan Hingorani; Sanjay Dixit; Miriam Johnson; Victoria Plested; Kevin Alty; Peter Colley; Andrew W Beavis; Rajarshi Roy; Anthony Maraveyas Journal: Cancer Res Treat Date: 2015-02-16 Impact factor: 4.679
Authors: Megan M Boniface; Sachin B Wani; Tracey E Schefter; Phillip J Koo; Cheryl Meguid; Stephen Leong; Jeffrey B Kaplan; Lisa J Wingrove; Martin D McCarter Journal: Cancer Manag Res Date: 2016-04-22 Impact factor: 3.989